Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
Masanori Asakura(National Cerebral and Cardiovascular Center), Shigeki Higashiyama(Osaka International Cancer Institute), Hiroshi Ishiguro, Michihiko Tada(University of Toronto), Hiroshi Asanuma(Meiji University of Integrative Medicine), Yulin Liao(Center for Life Sciences), Tsuyoshi Yoshinaka, Koichi Node(Saga University), Yasushi Matsumura(The University of Osaka), Hiroshi Ohmoto(Pennsylvania State University), Masafumi Kitakaze(Hanwa Memorial Hospital), Shoji Sanada(Kobe University Hospital), Hiroshi Takeda(Hokkaido University), Seiji Takashima(The University of Osaka), Fuminobu Ishikura(National Cerebral and Cardiovascular Center), Masatsugu Hori(Osaka National Hospital), Shintaro Beppu(Osaka Hospital)
Cited by 722
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system
|Journal of Clinical Investigation|2007|1k
Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein.
|Journal of Biological Chemistry|1992|349
Metformin Prevents Progression of Heart Failure in Dogs
|Circulation|2009|288
Physiological Diagnostic Criteria for Vascular Failure
|Hypertension|2018|282